Edesa Biotech, Inc. Common Shares (EDSA) Stock
Key stats
- Market cap
- $25.74M
- Price / Earnings ratio
- -1.8x
- EPS (TTM)
- -$1.69
- Volume
- Loading
- 52-week high
- $20.32
- 52-week low
- $0.72
Source: third-party data provider, as of October 17, 2026
Compare with EDSA
Recent news

EDSA Stock Soars More Than 700% So Far This Year: Wall Street Eyes Further Upside In Run Up To Acute Kidney Injury Data Reveal
EDSA Stock Soars More Than 700% So Far This Year: Wall Street Eyes Further Upside In Run Up To Acute Kidney Injury Data Reveal
EDSA

EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech?
EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech?
EDSA

Why Did EDSA Stock Rally More Than 70% Today?
Why Did EDSA Stock Rally More Than 70% Today?
EDSA
Technical indicators
- RSI 14
- 26.27
- MACD 12/26/9
- -0.44
- EMA 9 of MACD
- -0.34
- MACD histogram
- -0.09
- SMA 50
- $4.37
- Price below SMA 50
- EMA 50
- $4.35
- Price below EMA 50
- SMA 200
- $5.59
- Price below SMA 200
- EMA 200
- $4.68
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

EDSA Stock Soars More Than 700% So Far This Year: Wall Street Eyes Further Upside In Run Up To Acute Kidney Injury Data Reveal
EDSA Stock Soars More Than 700% So Far This Year: Wall Street Eyes Further Upside In Run Up To Acute Kidney Injury Data Reveal
EDSA

EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech?
EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech?
EDSA

Why Did EDSA Stock Rally More Than 70% Today?
Why Did EDSA Stock Rally More Than 70% Today?
EDSA
About Edesa Biotech, Inc. Common Shares
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Pardeep Nijhawan FRCPC, M.D. | CEO, Company Secretary & Director | 1971 |
| Mr. Peter John Weiler M.B.A, M.Sc. | Chief Financial Officer | 1969 |
| Dr. Michael J. Brooks M.B.A., Ph.D. | President | 1979 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 17, 2026
Technical indicators
- RSI 14
- 26.27
- MACD 12/26/9
- -0.44
- EMA 9 of MACD
- -0.34
- MACD histogram
- -0.09
- SMA 50
- $4.37
- Price below SMA 50
- EMA 50
- $4.35
- Price below EMA 50
- SMA 200
- $5.59
- Price below SMA 200
- EMA 200
- $4.68
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +169.6 | -59.0 | +21.5 | -34.1 | -9.4 | -11.9 | -33.4 |



